Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
Source: BioPharma Dive
You may also like
Gene Therapy Partners Aim to Enhance Protein Expression
Modular Antibody–ADC Click Chemistry Overcomes Tumor...
See, Blind Mice: Consortium’s Drugs Restore Sight
Genetic Study Links Excessive Sweating to Neurological...
Parkinson’s in the Clinic, Insilico enters Phase...
KRAS-Targeted Vaccine Crosses First Clinical Milestone...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.